Kelan Thomas, PharmD, MS, BCPS, BCPP
Mondays 3/8, 3/15, 3/22, 3/29, 4/5, 4/12, 4/19, 4/26, 5/3, 5/10, 5/17, 5/24
8-9:30PM Eastern Time (EST through March 13/EDT starting March 14)
$1,200 for 12-sessions
Optional CE certificate for $65
To obtain your certificate, the CE form must be filled out within 14 days of class completion.
A limited number of Diversity Fund scholarships are available, please complete this application.
This course can be taken in partial fulfillment of the requirements for the Fluence Postgraduate Certificate in Psychedelic Integration Therapy or Ketamine-assisted Psychotherapy.
This reading and study group will maintain the same membership for the 12-week period. The group will have a syllabus with readings that participants will be expected to read prior to each discussion group meeting. The format for each session will include a short review of each paper by the group leader, followed by a discussion of the content and group members’ perspectives of the topic. This is an active group and weekly participation is required. The group is ideal for clinicians, graduate students, researchers, or the public, so long as they have training or interest in the biological responses that may influence the efficacy and safety of psychedelic therapy. Readings will include publications in the academic literature. The articles will provide an overview of psychedelic effects investigated by a variety of scientific methods (pharmacodynamics, pharmacokinetics, pharmacogenomics, neuroscience) for several types of psychedelics (e.g., psilocybin, ayahuasca, MDMA, ketamine).
1. Describe pharmacokinetic properties of psilocybin to predict potential drug interactions and adverse effects
2. Describe pharmacokinetic properties of ayahuasca to predict potential drug interactions and adverse effects
3. Describe pharmacokinetic properties of MDMA to predict potential drug interactions and adverse effects
4. Describe pharmacokinetic properties of ketamine to predict potential drug interactions and adverse effects
5. Explain how the pharmacodynamics of psilocybin affects clinical and serological biomarkers
6. Explain how the pharmacodynamics of ayahuasca affects clinical and serological biomarkers
7. Explain how the pharmacodynamics of MDMA affects clinical and serological biomarkers
8. Explain how the pharmacodynamics of ketamine affects clinical and serological biomarkers
9. Discuss the effects of psilocybin on neural network function
10. Discuss the effects of ayahuasca on neural network function
11. Discuss the effects of MDMA on neural network function
12. Discuss the effects of ketamine on neural network function
Information on Continuing Education Credit for Health Professionals (CE)
• CE credits for psychologists are provided by the Spiritual Competency Academy (SCA) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content.
• The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association.
• LCSWs, MFTs, and other mental health professionals from states other than California need to check with their state licensing board as to whether or not they accept programs offered by approved sponsors of CE by the American Psychological Association.
• SCA is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California.
• SCA is an approved CE provider for National Board Certified Health and Wellness Coaches (CEP Number 100196)
• For questions about receiving your Certificate of Attendance, contact Elizabeth Nielson, firstname.lastname@example.org. For questions about CE, visit www.spiritualcompetency.com or contact David Lukoff, PhD at CE@spiritualcompetency.com.